Potentiation of cytotoxicity by combination of imatinib and chlorimipramine in glioma

International Journal of Oncology

Volumn 32, Issue 4, 2008, Pages 829-839

  Bilir, Ayhan ^a   Erguven, Mine ^b   Oktem, Gulperi ^c   Ozdemir, Aysegul ^d   Uslu, Atilla ^a   Aktas, Esin ^b   Bonavinda, Benjamin ^e  

^a ISTANBUL UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

^c EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^d Bakirkoy Hospital for Psychiatric and Neurological Diseases   (Turkey)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Autophagy; C6 glioma; Chlorimipramine; Imatinib mesylate; Spheroid culture

Indexed keywords

CLOMIPRAMINE; CYCLIC AMP; DNA; FLUORESCEIN ISOTHIOCYANATE; IMATINIB; LIPOCORTIN 5; ANTINEOPLASTIC AGENT; BROXURIDINE; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL CYCLE S PHASE; CELL DEATH; CELL KINETICS; CELL PROLIFERATION; CELL STRUCTURE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DNA SYNTHESIS INHIBITION; DRUG POTENTIATION; GLIOMA; HUMAN; HUMAN CELL; MONOLAYER CULTURE; NONHUMAN; PRIORITY JOURNAL; RAT; SCANNING ELECTRON MICROSCOPY; TIME; TRANSMISSION ELECTRON MICROSCOPY; ANIMAL; CELL CYCLE; CELL SURVIVAL; DRUG EFFECT; METABOLISM; PATHOLOGY; TUMOR CELL LINE; ULTRASTRUCTURE;

ANIMALS; ANNEXIN A5; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BROMODEOXYURIDINE; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CLOMIPRAMINE; CYCLIC AMP; DRUG SYNERGISM; GLIOMA; MICROSCOPY, ELECTRON, SCANNING; PIPERAZINES; PYRIMIDINES; RATS;

EID: 44449101761     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Arora A and Scholar EM: Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 315: 971-979, 2005.
2. Heinrich MC, Blanke CD, Druker BJ and Corless CL: Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 20: 1692-1703, 2002.
3. Buchdunger E, Cioffi CL, Law N, et al: Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295: 139-145, 2000.
4. Yu C, Krystal G, Dent P and Grant S: Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in BCR-ABL-positive human leukemia cells. Clin Cancer Res 8: 2976-2984, 2002.
5. Uziel O, Fenig E, Nordenberg J, et al: Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines. Br J Cancer 92: 1881-1891, 2005.
6. Deininger M, Buchdunger E and Druker BJ: The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105: 2640-2653, 2005.
7. Tarn C, Skorobogatko YV, Taguchi T, Eisenberg B, von Mehren M and Godwin AK: Therapeutic effect of imatinib in gastrointestinal stromal tumors: AKT signaling dependent and independent mechanisms. Cancer Res 66: 5477-5486, 2006.
8. Kilic T, Alberta JA, Zdunek PR, et al: Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. Cancer Res 60: 5143-5150, 2000.
9. Krystal GW, Honsawek S, Litz J and Buchdunger E: The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin Cancer Res 6: 3319-3326, 2000.
10. Mitsiades CS, Sykoutri D, McMullan C, Poulaki V and Mitsiades N: Effect of imatinib mesylate (Gleevec) on anaplastic thyroid carcinoma cell lines. J Clin Endocrinol Metab 88: 5043-5044, 2003.
11. Kim SJ, Uehara H, Yazici S, et al: Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer. J Natl Cancer Inst 98: 783-793, 2006.
12. O'Reilly T, Wartmann M, Maira SM, et al: Patupilone (epothilone B, EPO906) and imatinib (STI571, Glivec) in combination display enhanced antitumour activity in vivo against experimental rat C6 glioma. Cancer Chemother Pharmacol 55: 307-317, 2005.
13. Lokker NA, Sullivan CM, Hollenbach SJ, Israel MA and Giese NA: Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors. Cancer Res 62: 3729-3735, 2002.
14. Breedveld P, Pluim D, Cipriani G, et al: The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res 65: 2577-2582, 2005.
15. Hagerstrand D, Hesselager G, Achterberg S, et al: Characterization of an imatinib-sensitive subset of high-grade human glioma cultures. Oncogene 25: 4913-4922, 2006.
16. Trimble MR: Worldwide use of clomipramine. J Clin Psychiatry 51 (suppl): 51-58, 1990.
17. Steingart AB and Cotterchio M: Do antidepressants cause, promote, or inhibit cancers? J Clin Epidemiol 48: 1407-1412, 1995.
18. Sauter C: Cytostatic activity of commonly used tricyclic antidepressants. Oncology 46: 155-157, 1989.
19. Merry S, Hamilton TG, Flanigan P, Freshney RI and Kaye SB: Circumvention of pleiotropic drug resistance in subcutaneous tumours in vivo with verapamil and clomipramine. Eur J Cancer 27: 31-34, 1991.
20. Rooprai HK, Christidou M and Pilkington GJ: The potential for strategies using micronutrients and heterocyclic drugs to treat invasive gliomas. Acta Neurochir (Wien) 145: 683-690, 2003.
21. Xia Z, Lundgren B, Bergstrand A, De Pierre JW and Nassberger L: Changes in the generation of reactive oxygen species and in mitochondrial membrane potential during apoptosis induced by the antidepressants imipramine, clornipramine and citalopram and the effects on these changes by Bcl-2 and Bcl-X(L). Biochem Pharmacol 57: 1199-1208, 1999.
22. Daley E, Wilkie D, Loesch A, Hargreaves IP, Kendall DA, Pilkington GJ and Bates TE: Chlorimipramine: a novel anticancer agent with a mitochondrial target. Biochem Biophys Res Commun 328: 623-632, 2005.
23. Castaing M, Brouant P, Loiseau A, et al: Membrane permeation by multidrug-resistance-modulators and non-modulators: effects of hydrophobicity and electric charge. J Pharm Pharmacol 52: 289-296, 2000.
24. Pommerenke EW and Volm M: Reversal of doxorubicin-resistance in solid tumors by clomipramine. In Vivo 9: 99-101, 1995.
25. Sathornsumetee S, Reardon DA, Desjardins A, Quinn JA, Vredenburgh JJ and Rich JN: Molecularly targeted therapy for malignant glioma. Cancer 110: 13-24, 2007.
26. Widakowich C, De Azambuja E, Gil T, et al: Molecular targeted therapies in breast cancer: Where are we now? Int J Biochem Cell Biol (In press).
27. Altinoz MA, Bilir A, Del Maestro RF, Tuna S, Ozcan E and Gedikoglu G: Noscapine and diltiazem augment taxol and radiation-induced S-phase arrest and clonogenic death of C6 glioma in vitro. Surg Neurol 65: 478-485, 2006.
28. Kaygisiz Z, Erkasap N, Yazihan N, et al: Erythropoietin changes contractility, cAMP and nitrite levels of isolated rat hearts. J Physiol Sci 56: 247-251, 2006.
29. Harper JF, Brooker G, Harper JF, et al: Femtomole sensitive radioimmunoassay for cyclic AMP and cyclic GMP after 2′0 acetylation by acetic anhydride in aqueous solution. J Cyclic Nucleotide Res 1: 207-218, 1975.
30. Ugur O and Onaran HO: Allosteric equilibrium model explains steady-state coupling of β-adrenergic receptors to adenylate cyclase in turkey erythrocyte membranes. Biochem J 323: 765-776, 1997.
31. Chou TC and Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55, 1984.
32. Chou TC and Talalay P: Analysis of combined drug effects: a new look at a very old problem. Trends Pharmacol Sci 4: 450-454, 1983.
33. Sacks PG, Harris D and Chou TC: Modulation of growth and proliferation in squamous cell carcinoma by retinoic acid: a rationale for combination therapy with chemotherapeutic agents. Int J Cancer 61: 409-415, 1995.
34. Dai H, Marbach P, Lemaire M, Hayes M and Elmquist WF: Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux. J Pharmacol Exp Ther 304: 1085-1092, 2003.
35. Sokolowska P and Nowak JZ: Constitutive activity of beta-adrenergic receptors in C6 glioma cells. Pharmacol Rep 57: 659-663, 2005.
36. Grobben B, De Deyn PP and Slegers H: Rat C6 glioma as experimental model system for the study of glioblastoma growth and invasion. Cell Tissue Res 310: 257-270, 2002.
37. Jaiswal BS and Conti M: Calcium regulation of the soluble adenylyl cyclase expressed in mammallian spermatozoa. Proc Natl Acad Sci USA 100: 10676-10681, 2003.
38. Baillie GS and Houslay MD: Arrestin times for compartmentalised cAMP signalling and phosphodiesterase-4 enzymes. Curr Opin Cell Biol 17: 129-134, 2005.
39. Takagi A, Watanabe M, Ishii Y, et al: Three-dimensional cellular spheroid formation provides human prostate tumor cells with tissue-like features. Anticancer Res 27: 45-53, 2007.
40. Sutherland R, Carlsson J, Durand R and Yuhas J: Spheroids in cancer research. Cancer Res 41: 2980-2984, 1981.
41. Ertmer A, Huber V, Gilch S, et al: The anticancer drug imatinib induces cellular autophagy. Leukemia 21: 936-942, 2007.
42. Carew JS, Nawrocki ST and Cleveland JL: Modulating autophagy for therapeutic benefit. Autophagy (In press).
43. Carew JS, Nawrocki ST, Kahue CN, et al: Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr- Abl-mediated drug resistance. Blood (In press).
44. Lainesse C, Frank D, Meucci V, Intorre L, Soldani G and Doucet M: Pharmacokinetics of clomipramine and desmethyl-clomipramine after single-dose intravenous and oral administrations in cats. J Vet Pharmacol Ther 29: 271-278, 2006.
45. Xia Z, Bergstrand A, De Pierre JW and Nassberger L: The antidepressants imipramine, clomipramine, and citalopram induce apoptosis in human acute myeloid leukemia HL-60 cells via caspase-3 activation. J Biochem Mol Toxicol 13: 338-347, 1999.
46. Levkovitz Y, Gil-Ad I, Zeldich E, Dayag M and Weizman A: Differential induction of apoptosis by antidepressants in glioma and neuroblastoma. cell lines: evidence for p-c-Jun, cytochrome c, and caspase-3 involvement. J Mol Neurosci 27: 29-42, 2005.
47. Daley E, Wilkie D, Loesch A, Hargreaves IP, Kendall DA, Pilkington GJ and Bates TE: Chlorimipramine: a novel anticancer agent with a mitochondrial target. Biochem Biophys Res Commun 328: 623-632, 2005.
48. Ramakrishnan P: The Role of P-glycoprotein in the Blood-Brain Barrier. Einstein Q J Biol Med 19: 160-165, 2003.